Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma

Kris Thielemans; Bart Neyns; Sofie Wilgenhof; Jurgen Corthals; Carlo Heirman

doi:10.1186/2051-1426-2-S3-P129

Citation Tools

Poster Presentation

Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Thielemans K, Neyns B, Wilgenhof S, et al

Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma

Journal for ImmunoTherapy of Cancer 2014;2:P129. doi: 10.1186/2051-1426-2-S3-P129

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password